Other formats:
BibTeX
LaTeX
RIS
@article{1605051, author = {Krejčí, Pavel}, article_location = {Waltham}, article_number = {13}, doi = {http://dx.doi.org/10.1056/NEJMc1910394}, keywords = {Achondroplasia; C-type natriuretic peptide}, language = {eng}, issn = {0028-4793}, journal = {New England Journal of Medicine}, title = {C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia}, url = {http://dx.doi.org/10.1056/NEJMc1910394}, volume = {381}, year = {2019} }
TY - JOUR ID - 1605051 AU - Krejčí, Pavel PY - 2019 TI - C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia JF - New England Journal of Medicine VL - 381 IS - 13 SP - 1291 EP - 1291 PB - Massachussetts Medical Society SN - 00284793 KW - Achondroplasia KW - C-type natriuretic peptide UR - http://dx.doi.org/10.1056/NEJMc1910394 L2 - http://dx.doi.org/10.1056/NEJMc1910394 N2 - Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications. ER -
KREJČÍ, Pavel. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. \textit{New England Journal of Medicine}. Waltham: Massachussetts Medical Society, 2019, vol.~381, No~13, p.~1291. ISSN~0028-4793. Available from: https://dx.doi.org/10.1056/NEJMc1910394.
|